Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
Should GLP-1 receptor agonists be used with caution in high risk population for colorectal cancer
Glucose-dependent insulinotropic polypeptide, or GIP, works alongside GLP-1 to improve insulin sensitivity and lipid metabolism
GLP-1 therapies , including semaglutide or tirzepatide , are administered under the close supervision of our medical team, ensuring dosing levels align precisely with original FDA clinical trials.Patients also receive ongoing nutrition and lifestyle counseling , with access to their care team around the clock for guidance, support, and side-effect management
Read more here: nature.com/articles/s4143 #Ophthalmology With #GLP-1 receptor agonists like semaglutide rising in use for diabetes & obesity, concerns are surfacing about possible ocular side effectsespecially NAION, a serious optic neuropathy
In the late 2000s, still haunted by the fallout from drugs like rosiglitazone (brand name Avandia), linked to increased heart attack risk, the FDA laid down a blunt new rule: every new diabetes drug must prove it wont harm the heart before it ever sees pharmacy shelves
